Position in ZYME
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,591,246
+$216,976 QoQ
Shares Held
60,874
+10.9% QoQ
Ownership
0.086%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#77
of 202 holders
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $71,968,852 across 46 Biotechnology names. ZYME ranks #17 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in ZYME
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,591,246 | 60,874 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $1,374,270 | 54,883 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $884,372 | 33,588 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $554,980 | 32,493 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $188,061 | 14,985 | Shares | Sole | 2025-08-07 | |
| 2024-06-30 | $258,389 | 30,363 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||